초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 08월 18일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제108회 대한화학회 학술발표회, 총회 및 기기전시회 Lung cancer biomarker discovery by glycoproteomics approaches

2011년 8월 11일 11시 15분 30초
BIO1-2 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
목 14시 : 25분
생명화학 - Biomedical Research of Glycoprotein by Mass Spectrometry
저자 및
School of Dentistry, Kyungbook National University, Korea
Human lung cancer is a major cause of cancer mortality worldwide. Understanding the pathophysiological features and the development of novel biomarkers for diagnosis as well as treatment are major tasks. In this presentation, I will show some of our recent lung cancer proteome biomarker development by glycoproteomic approaches and their validation processes. Sera from the patients of lung adenocarcinoma, squamous cell lung cancer, and small cell lung cancers were depleted of the abundant proteins such as albumin and immunoglobulin via an immunoaffinity method. Then the sera were further subjected to total glycoprotein enrichment by multilectin column or fucosylated protein enrichment by Aleuria aurantia lectin (ALL) column. Enriched total glycoproteins or fucosylated glycoproteins were resolved by SDS-PAGE and digested with trypsin and subsequently analyzed by LC-ESI-MS/MS. From comparative proteomic analysis, we identified Plasma Kallikrein, Haptoglobin beta chain, Complement component 9, Serum Paraoxygenase, etc as a potential lung cancer biomarkers. These biomarkers were validated by Western blot, tissue microarray, lectin-hybrid ELISA, protein chips, etc. Then, we pursued to develop a pair of target specific monoclonal antibodies which can be used for the pair-test assay development. After optimization of the test kits, we finally used them for the test of the sera from lung cancer patients, healthy controls and other samples in several hundred cases. Our results showed that the glycoproteomics approaches are useful for the discovery of lung cancer biomarkers and diagnostic assay development using the biomarkers.